BryoLogyx Appoints Oncology Leaders, Drs. Richard Schilsky and Justin Stebbing, to Scientific and Medical Advisory Board

biospace.com/article/releases/bryologyx-appoints-oncology-leaders-drs-richard-schilsky-and-justin-stebbing-to-scientific-and-medical-advisory-board/

DANVILLE, CA—(MAY 26) -- BryoLogyx Inc., announced today that the Company has named two cancer research leaders, Richard L. Schilsky, MD, FACP, FSCT, FASCO; and Justin Stebbing, MD, PhD to its Scientific and Medical Advisory Board. Dr. Schilsky is former President, Chief Medical Officer and Executive Vice President of ASCO and former Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center. Dr. Stebbing is Professor of Cancer Medicine and Oncology at Imperial College London.

“The addition of these two-world class thought leaders in clinical oncology and cancer research will strengthen our program to develop our lead compound, bryostatin-1, to address key resistance mechanisms in immuno-oncology,” said Thomas Loarie, Co-Founder and CEO of BryoLogyx. “We look forward to their guidance, particularly as we prepare to enter our first clinical trials to evaluate bryostatin-1’s potential to enhance immunotherapies by upregulating tumor antigen targets.”

Dr. Schilsky has spent most of his career at the University of Chicago, where he joined the faculty in 1984, subsequently rising to Professor of Medicine and serving in many roles, including Associate Dean for Clinical Research in the Biological Sciences Division and Director of the University of Chicago Cancer Research Center. He brings extensive experience working with both the National Cancer Institute (NCI), as chair of the NCI Board of Scientific Advisors and as a member of the NCI Clinical and Translational Research Committee, and the Food and Drug Administration as a member and chair of the Agency’s Oncologic Drugs Advisory Committee. Dr. Schilsky has served on the editorial boards of many cancer journals, including the *Journal of Clinical Oncology* and he currently serves on the editorial board of *The New England Journal of Medicine*.

[A1]

Dr. Stebbing has published over 600 peer-reviewed papers in journals such as *The Lancet, The New England Journal, Blood, the Journal of Clinical Oncology,* and *Annals of Internal Medicine*. His research focus at Imperial is on new therapies in cancer, and the systemic management of patients with solid malignancies including a number of new biomarker-based approaches, with an emphasis on circulating tumor cells and cell free DNA. Dr. Stebbing's laboratory work is concentrated on new druggable target discovery and gene regulation examining the role of non-coding RNAs in stem cells. He originally studied medicine at Trinity College, Oxford, prior to a residency at the Johns Hopkins Hospital then a PhD examining the interplay between the immune system and cancer.

He is a Fellow of the Royal College of Physicians and the Royal College of Pathologists and sits on advisory Boards of a number of international cancer committees. He has an extensive clinical practice and links this to a wide number of translational research studies and immunotherapy trials. As a consequence of his unique background, led international collaborations to develop baricitinib as a treatment during the COVID-19 outbreak, having published artificial intelligence-based research on its dual anti-viral/anti-cytokine mechanism at the start of the pandemic, ultimately leading to its US FDA emergency use authorization.

About BryoLogyx

BryoLogyx is developing a new class of drugs to address resistance mechanisms in immuno-oncology. The company is capitalizing on: the discovery that its lead compound, bryostatin-1, upregulates key I/O targets in hematological cancers; its potential to reverse T-cell exhaustion; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling its commercial development. BryoLogyx has exclusive rights from Stanford University to this novel synthesis for cancer and certain other indications. Bryostatin-1, which has an established clinical safety profile, is expected to enter clinical trials in I/O later this year through a collaboration with the NCI. Learn more at *www.bryologyx.com.*